Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy
This is a phase IV, single-center, prospective, open-label, randomized,controlled study
Primary Breast Cancer
DRUG: Vinorelbine
distant disease-free survival (DDFS), 5 years after surgery
relapse-free survival（RFS）、overall survival（OS）, 5 years after surgery
This is a phase IV, single-center, prospective, open-label, randomized,controlled study